According to global cancer statistics, millions of new cases of prostate cancer are diagnosed each year, making it a major focus area in oncology research.

Advancements in molecular biology, biomarker discovery, precision medicine, and immunotherapy have significantly expanded the scope of prostate cancer research, but these breakthroughs depend heavily on access to high-quality biospecimens.

At Bay Biosciences, we understand the critical need for reliable biospecimens to support prostate cancer research. We provide ethically sourced human prostate cancer tissue, serum and plasma, fresh frozen tissue, and other blood-derived samples obtained from patients across a wide range of disease stages.

These prostate cancer samples help researchers investigate biomarkers such as prostate-specific antigen, evaluate disease progression, and develop improved diagnostics and therapies.

Prostate Cancer Tissue

Understanding Prostate Cancer

Prostate cancer develops in the prostate gland, a small walnut-shaped organ located below the bladder in men.

The prostate produces seminal fluid that nourishes and transports sperm. When cells in this gland begin to grow uncontrollably due to genetic mutations, a tumor may form.

The progression of prostate cancer varies widely.

Some tumors grow slowly and remain confined to the prostate for many years, while others become aggressive and spread to nearby tissues or distant organs.

Clinicians classify the disease according to prostate cancer stage, which describes the extent of tumor growth and spread.

Stage 1 Prostate Cancer

Stage 1 prostate cancer represents the earliest stage of the disease.

At this point:

  • The tumor is very small.
  • Cancer is confined entirely to the prostate gland.

Because tumors are localized and slow-growing, the prognosis is generally good.

Stage 2 Prostate Cancer

In stage 2 prostate cancer, the tumor remains confined to the prostate but is larger or involves more of the gland.

Characteristics may include:

  • Higher prostate-specific antigen levels
  • Increased tumor volume
  • Greater likelihood of progression compared to stage 1

Stage 3 Prostate Cancer

Stage 3 prostate cancer indicates that the tumor has extended beyond the prostate capsule into nearby tissues, such as:

  • Seminal vesicles
  • Surrounding connective tissue

Although the cancer has not spread to distant organs, it is considered locally advanced and requires more aggressive treatment.

Stage 4 Prostate Cancer

Stage 4 prostate cancer is the most advanced stage. The cancer may have spread to:

  • Lymph nodes
  • Bones
  • Liver
  • Lungs

Metastatic prostate cancer presents significant treatment challenges and often requires systemic therapies.

Moreover, treatment plans also incorporate medicines that can kill prostate cells that are present anywhere in the body.

Common Symptoms of Prostate Cancer

In its early stages, prostate cancer often produces no noticeable symptoms.

As the disease progresses, patients may experience urinary and systemic symptoms such as:

Risk Factors

The exact cause of prostate cancer is not fully understood, but researchers have identified several genetic and environmental risk factors.

Age

Age is the most significant risk factor because the majority of prostate cancer cases occur in men over the age of 50.

Genetic Mutations

Certain inherited mutations increase susceptibility to prostate cancer. Variants in genes such as BRCA1, BRCA2, and HOXB13 have been associated with increased risk.

Family History

Men with a father or brother diagnosed with prostate cancer are significantly more likely to develop the disease.

Race

The incidence of prostate cancer is significantly higher among African American men compared with White men. In addition to having a greater likelihood of developing the disease, African American men are also more likely to experience more aggressive forms of prostate cancer and have higher mortality rates.

Diagnosis Methods

Accurate diagnosis of prostate cancer requires a combination of clinical evaluation, laboratory testing, imaging, and histopathological analysis.

1. Prostate Cancer Screening

Early detection programs rely heavily on prostate cancer screening. This typically includes Digital Rectal Examination (DRE) and blood testing for Prostate-Specific Antigen. Screening helps clinicians detect potential abnormalities before symptoms appear.

2. Digital Rectal Examination (DRE)

A Digital Rectal Examination (DRE) involves a clinician inserting a gloved, lubricated finger into the rectum to feel the prostate gland and detect irregularities. These may include any hard areas, lumps, or asymmetry.

While DRE cannot definitively diagnose prostate cancer on its own and is not always recommended either, it may help guide further diagnostic procedures such as imaging or biopsy.

3. Prostate Specific Antigen Testing 

Prostate-specific antigen (PSA) is a protein produced by prostate cells. Elevated PSA levels in the blood may indicate problems such as:

  • Prostate cancer
  • Benign prostatic hyperplasia
  • Prostatitis

PSA testing is also not definitive, but it is still widely used as a primary screening tool.

4. Imaging Studies

Imaging techniques help visualize prostate abnormalities and determine disease spread.

Common methods include:

5. Prostate Biopsy

The definitive diagnosis of prostate cancer requires a biopsy. During this procedure, clinicians collect Human Prostate Cancer Tissue samples from the prostate gland for microscopic examination.

Pathologists analyze these tissues to:

  • Confirm malignancy
  • Determine tumor grade (Gleason score)
  • Assess tumor aggressiveness

Treatment Options

Treatment strategies vary depending on cancer stage, tumor aggressiveness, and patient health.

Some common treatment methods are: 

Active Surveillance:

For patients with low-risk disease, physicians may recommend monitoring the tumor rather than immediate treatment. Active surveillance involves regular PSA testing, imaging, and periodic biopsies.

Surgery:

Radical prostatectomy involves the surgical removal of the prostate gland as well as surrounding tissues.

Radiation Therapy:

Radiation therapy uses high-energy beams in order to destroy cancer cells. It can be delivered as external beam radiation or brachytherapy (internal radiation).

Hormone Therapy:

Prostate cancer cells depend on androgens for their growth. Hormone therapy reduces testosterone levels or blocks its effects.

Chemotherapy:

Chemotherapy may be used for advanced or metastatic disease.

Many of these treatments are developed through research using carefully collected prostate cancer samples and blood-derived biospecimens.

Importance of Serum and Plasma for Prostate Cancer Research

While tumor tissue provides direct insight into cancer biology, blood-derived biospecimens such as serum and plasma are equally critical for advancing prostate cancer research.

Serum and plasma samples enable researchers to detect circulating biomarkers, including:

  • Prostate-specific antigen
  • Circulating tumor DNA (ctDNA)
  • Extracellular vesicles
  • MicroRNAs

These biomarkers can help identify early disease, monitor progression, and evaluate treatment response.

Longitudinal Biospecimen Collection

Repeated serum and plasma collection allows researchers to monitor disease progression from stage 1 prostate cancer through advanced stages such as stage 3 prostate cancer and stage 4 prostate cancer.

It also provides critical insights into tumor evolution, treatment resistance mechanisms, and metastatic progression.

Supporting Your Research with Bay Biosciences

Access to high-quality biospecimens is essential for advancing prostate cancer research and developing next-generation diagnostics and therapies.

As one of the trusted suppliers of fresh frozen prostate tumor biopsies, Bay Biosciences ensures that biospecimens meet strict quality control protocols and are suitable for a wide range of research applications.

Our comprehensive range of biospecimens includes:

If you have any questions, concerns, or special requests, please don’t hesitate to reach out to us!